The Latest Cardiac and Vascular News
– ACCESS 2 is a randomized clinical trial evaluating Sirogen for improving hemodialysis AV Fistula outcomes – CRESSKILL, N.J., Aug. 29, 2022 /PRNewswire/ — Vascular Therapies, Inc. a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, today announced that the first patient in the ACCESS 2 clinical trial was enrolled at […]
– Proceeds to fund ACCESS 2 – a randomized clinical trial evaluating Sirogen™ for improving hemodialysis AV Fistula outcomes in high-risk patients – CRESSKILL, N.J., March 29, 2022 /PRNewswire/ — Vascular Therapies, Inc. a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, today announced the closing of a $25 million private financing. The […]
– Sirogen™ Shows Encouraging AV Fistula Outcomes in Elderly End-Stage Renal Disease Patients – CRESSKILL, N.J., Nov. 4, 2021 /PRNewswire/ — Vascular Therapies, a privately held biotechnology company is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today, the company announced the presentation of clinical results from its […]
– Sirogen™ Shows Encouraging AV Fistula Outcomes in Elderly End-Stage Renal Disease Patients – CRESSKILL, N.J.–(BUSINESS WIRE)–Vascular Therapies, a privately held biotechnology company is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which […]
– Company funded through 2020. Topline Phase 3 results for Sirogen expected to be announced in Q2 2020 – CRESSKILL, N.J, January 28, 2020 – Vascular Therapies, a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, today announced the closing of an upsized $17.3 million private financing. The financing […]
CRESSKILL, N.J., Sept. 9, 2019 /PRNewswire/ — Vascular Therapies, a clinical stage biotechnology company, is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local, perivascular drug delivery focused on improving vascular access outcomes in patients with kidney disease. Daniel G. Clair, MD, vascular surgeon and Chairman of the Department of Surgery at Palmetto Health-USC Medical Group in Columbia, South Carolina presented […]
CRESSKILL, N.J., Jan. 9, 2019 /PRNewswire/ — Vascular Therapies, a biotechnology company focused on improving outcomes for patients with advanced kidney disease, today announced the appointment of John McDermott as the Company’s Chief Executive Officer. Bob Croce, Chairman of the Board of Directors of Vascular Therapies, Inc. commented, “We are very pleased to welcome John as our Chief Executive Officer. […]
CRESSKILL, N.J., Nov. 9, 2017 /PRNewswire/ — An innovative, investigational treatment approach is showing the potential to address an important, unresolved problem encountered by patients with kidney failure on dialysis. At the recent annual meeting of the American Society of Nephrology (ASN), Vascular Therapies, Inc. presented preliminary results relating to analysis of the first 18 […]
